1 Title

- 2 Benchmarking saliency methods for chest X-ray interpretation
- 3

4 Authors

- 5 Adriel Saporta MS MBA^{1*}, Xiaotong Gui MS^{2*}, Ashwin Agrawal MS^{2*}, Anuj Pareek MD
- 6 PhD³, Steven QH Truong MBA⁴, Chanh DT Nguyen PhD^{4,5}, Van-Doan Ngo MD⁶, Jayne
- 7 Seekins DO⁷, Francis G. Blankenberg MD⁷, Andrew Y. Ng PhD², Matthew P. Lungren MD
- 8 MPH³, Pranav Rajpurkar PhD⁸
- 9

10 Affiliations

- ¹¹ ¹Department of Computer Science, New York University, USA
- 12 ²Department of Computer Science, Stanford University, USA
- ¹³ ³Stanford Center for Artificial Intelligence in Medicine and Imaging, USA
- 14 ⁴VinBrain, Vietnam
- 15 ⁵VinUniversity, Vietnam
- 16 ⁶Vinmec International Hospital, Vietnam
- ¹⁷ ⁷Department of Radiology, Stanford University School of Medicine, USA
- 18 ⁸Department of Biomedical Informatics, Harvard University, USA
- ¹⁹ ^{*}These authors contributed equally: Adriel Saporta, Xiaotong Gui, Ashwin Agrawal
- 20
- 21 Corresponding author: Pranav Rajpurkar, PhD (pranav_rajpurkar@hms.harvard.edu)
- 22
- 23 Current word count: 4438

24 Abstract

25 Saliency methods, which "explain" deep neural networks by producing heat maps that 26 highlight the areas of the medical image that influence model prediction, are often 27 presented to clinicians as an aid in diagnostic decision-making. Although many saliency 28 methods have been proposed for medical imaging interpretation, rigorous investigation 29 of the accuracy and reliability of these strategies is necessary before they are integrated 30 into the clinical setting. In this work, we quantitatively evaluate seven saliency methods-31 including Grad-CAM, Grad-CAM++, and Integrated Gradients-across multiple neural 32 network architectures using two evaluation metrics. We establish the first human 33 benchmark for chest X-ray segmentation in a multilabel classification set up, and examine 34 under what clinical conditions saliency maps might be more prone to failure in localizing 35 important pathologies compared to a human expert benchmark. We find that (i) while 36 Grad-CAM generally localized pathologies better than the other evaluated saliency methods, all seven performed significantly worse compared with the human benchmark; 37 38 (ii) the gap in localization performance between Grad-CAM and the human benchmark 39 was largest for pathologies that had multiple instances, were smaller in size, and had 40 shapes that were more complex; (iii) model confidence was positively correlated with 41 Grad-CAM localization performance. While it is difficult to know whether poor localization 42 performance is attributable to the model or to the saliency method, our work demonstrates 43 that several important limitations of saliency methods must be addressed before we can 44 rely on them for deep learning explainability in medical imaging.

45

46 Introduction

47 Deep learning has enabled automated medical imaging interpretation at the level of practicing experts in some settings^{1–3}. While the potential benefits of automated 48 49 diagnostic models are numerous, lack of model interpretability in the use of "black-box" deep neural networks (DNNs) represents a major barrier to clinical trust and adoption^{4–6}. 50 51 In fact, it has been argued that the European Union's recently adopted General Data 52 Protection Regulation (GDPR) affirms an individual's right to an explanation in the context 53 of automated decision-making⁷. Although the importance of DNN interpretability is widely 54 acknowledged and many techniques have been proposed, little emphasis has been 55 placed on how best to quantitatively evaluate these explainability methods⁸.

56

57 One type of DNN interpretation strategy widely used in the context of medical imaging is 58 based on saliency (or pixel-attribution) methods⁹⁻¹². Saliency methods produce heat 59 maps highlighting the areas of the medical image that most influenced the DNN's 60 prediction. Since saliency methods provide post-hoc interpretability of models that are 61 never exposed to bounding box annotations or pixel-level segmentations during training, 62 they are particularly useful in the context of medical imaging where ground-truth 63 segmentations can be especially time-consuming and expensive to obtain. The heat 64 maps help to visualize whether a DNN is concentrating on the same regions of a medical 65 image that a human expert would focus on, rather than concentrating on a clinically 66 irrelevant part of the medical image or even on confounders in the image^{13–15}. Saliency 67 methods have been widely used for a variety of medical imaging tasks and modalities 68 including, but not limited to, visualizing the performance of a convolutional neural network 69 (CNN) in predicting (1) myocardial infarction¹⁶ and hypoglycemia¹⁷ from

electrocardiograms, (2) visual impairment¹⁸, refractive error¹⁹, and anaemia²⁰ from retinal 70 photographs, (3) long-term mortality²¹ and tuberculosis²² from chest X-ray (CXR) images, 71 and (4) appendicitis²³ and pulmonary embolism²⁴ on computed tomography scans. 72 73 However, recent work has shown that saliency methods used to validate model 74 predictions can be misleading in some cases and may lead to increased bias and loss of 75 user trust in high-stakes contexts such as healthcare^{25–28}. Therefore, a rigorous 76 investigation of the accuracy and reliability of these strategies is necessary before they are integrated into the clinical setting²⁹. 77

78

79 In this work, we perform a systematic evaluation of seven common saliency methods in 80 medical imaging (Grad-CAM³⁰, Grad-CAM++³¹, Integrated Gradients³², Eigen-CAM⁴¹, 81 DeepLIFT⁴², Layer-Wise Relevance Propagation⁴³, and Occlusion⁴⁴) using three common CNN architectures (DenseNet121³³, ResNet152³⁴, Inception-v4³⁵). In doing so, we 82 83 establish the first human benchmark in CXR segmentation by collecting radiologist segmentations for 10 pathologies using CheXpert, a large publicly available CXR 84 dataset³⁶. To compare saliency method segmentations with expert segmentations, we 85 86 use two metrics to capture localization accuracy: (1) mean Intersection over Union, a 87 metric that measures the overlap between the saliency method segmentation and the 88 expert segmentation, and (2) hit rate, a less strict metric than mIoU that does not require 89 the saliency method to locate the full extent of a pathology. We find that (1) while Grad-90 CAM generally localizes pathologies more accurately than the other evaluated saliency 91 methods, all seven perform significantly worse compared with a human radiologist 92 benchmark (although it is difficult to know whether poor localization performance is

93 attributable to the model or to the saliency method); (2) the gap in localization 94 performance between Grad-CAM and the human benchmark is largest for pathologies 95 that have multiple instances on the same CXR, are smaller in size, and have shapes that 96 are more complex; (3) model confidence is positively correlated with Grad-CAM 97 localization performance. We publicly release a development dataset of expert 98 segmentations, which we call CheXlocalize, to facilitate further research in DNN 99 explainability for medical imaging.

100

101 **Results**

102 Framework for evaluating saliency methods

103 Seven methods were evaluated—Grad-CAM, Grad-CAM++, Integrated Gradients, Eigen-104 CAM, DeepLIFT, Layer-Wise Relevance Propagation (LRP), and Occlusion-in a multi-105 label classification setup on the CheXpert dataset (Fig. 1a). We ran experiments using 106 three CNN architectures previously used on CheXpert: DenseNet121, ResNet152, and 107 Inception-v4. For each combination of saliency method and model architecture, we 108 trained and evaluated an ensemble of 30 CNNs (see Methods for ensembling details). 109 We then passed each of the CXRs in the dataset's holdout test set into the trained ensemble model to obtain image-level predictions for the following 10 pathologies: 110 111 Atelectasis, Cardiomegaly, Consolidation, Edema, Enlarged Cardiomediastinum, Lung 112 Lesion, Lung Opacity, Pleural Effusion, Pneumothorax, and Support Devices. Of the 14 113 observations labeled in the CheXpert dataset: Fracture and Pleural Other were not 114 included in our analysis because they had low prevalence in our test set (fewer than 10 115 examples); Pneumonia was not included because it is a clinical (as opposed to a

medRxiv preprint doi: https://doi.org/10.1101/2021.02.28.21252634; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

116 radiological) diagnosis; and No Finding was not included because it is not applicable to 117 evaluating localization performance. For each CXR, we used the saliency method to 118 generate heat maps, one for each of the 10 pathologies, and then applied a threshold to 119 each heat map to produce binary segmentations (top row, Fig. 1a). Thresholding is 120 determined per pathology using Otsu's method³⁷, which iteratively searches for a 121 threshold value that maximizes inter-class pixel intensity variance. We also conducted a 122 second thresholding scheme in which we iteratively search for a threshold value that 123 maximizes per pathology mIoU on the validation set. Both thresholding schemes reported 124 similar findings (see Extended Data Fig. 1). The result shows that our evaluation of 125 localization performance is robust to different saliency map thresholding schemes. 126 Additionally, to calculate the hit rate evaluation metric (described below), we extracted 127 the pixel in the saliency method heat map with the largest value as the single most 128 representative point on the CXR for that pathology.

129

130 We obtained two independent sets of pixel-level CXR segmentations on the holdout test 131 set: ground-truth segmentations drawn by two board-certified radiologists (middle row, 132 Fig. 1a) and human benchmark segmentations drawn by a separate group of three board-133 certified radiologists (bottom row, Fig. 1a). The human benchmark segmentations and the 134 saliency method segmentations were compared with the ground-truth segmentations to 135 establish the human benchmark localization performance and the saliency method 136 localization performance, respectively. Additionally, for the hit rate evaluation metric, the 137 radiologists who drew the benchmark segmentations were also asked to locate a single 138 point on the CXR that was most representative of the pathology at hand (see

Supplementary Figs. S1 through S11 for detailed instructions given to the radiologists).
Note that the human benchmark localization performance demonstrates interrater
variability, and we use it as a reference when evaluating saliency method pipelines.

142

143 We used two evaluation metrics to compare segmentations (Fig. 1b). First, we used *mean* 144 Intersection over Union (mIoU), a metric that measures how much, on average, either the 145 saliency method or benchmark segmentations overlapped with the ground-truth 146 segmentations. Second, we used hit rate, a less strict metric that does not require the 147 saliency method or benchmark annotators to locate the full extent of a pathology. Hit rate is based on the pointing game setup³⁸, in which credit is given if the most representative 148 149 point identified by the saliency method or the benchmark annotators lies within the 150 ground-truth segmentation. A "hit" indicates that the correct region of the CXR was located regardless of the exact bounds of the binary segmentations. Localization 151 performance is then calculated as the hit rate across the dataset³⁹. In addition, we report 152 153 the sensitivity and specificity values of the saliency method pipeline and the human 154 benchmark in Extended Data Fig. 2.



loU: 0.078 | hit rate: hit Pleural Effusion

155

IoU: 0.682 | hit rate: miss Enlarged Cardiomediastinum

156 Fig. 1 | Framework for evaluating saliency methods. a, Top row left: a CXR image from the holdout test set is passed into an ensemble CNN trained only on CXR images 157 158 and their corresponding pathology task labels. Saliency method is used to generate 10 159 heat maps for the example CXR, one for each task. The pixel in the heat map with the largest value is determined to be the single most representative point on the CXR for 160 161 that pathology. Top row middle: there are three pathologies present in this CXR (Airspace Opacity, Pleural Effusion, and Support Devices). Top row right: a threshold is applied to 162 the heat maps to produce binary segmentations for each present pathology. Middle row: 163 Two board-certified radiologists were asked to segment the pathologies that were 164 165 present in the CXR as determined by the dataset's ground-truth labels. Saliency method 166 annotations are compared to these ground-truth annotations to determine "saliency method localization performance". Bottom row: Two board-certified radiologists 167 168 (separate from those in middle row) were also asked to segment the pathologies that were present in the CXR as determined by the dataset's ground-truth labels. In addition, 169

most representative point

170 these radiologists were asked to locate the single point on the CXR that was most 171 representative of each present pathology. These benchmark annotations are compared 172 to the ground-truth annotations to determine "human benchmark localization 173 performance". b, Left: CXR with ground-truth and saliency method annotations for 174 Pleural Effusion. The segmentations have a low overlap (IoU is 0.078), but pointing game 175 is a "hit" since the saliency method's most representative point is inside of the ground-176 truth segmentation. Right, CXR with ground-truth and human benchmark annotations 177 for Enlarged Cardiomediastinum. The segmentations have a high overlap (IoU is 0.682), 178 but pointing game is a "miss" since saliency method's most representative point is 179 outside of the ground-truth segmentation.

180

181 Evaluating localization performance

182 In order to compare the localization performance of the saliency methods with the human 183 benchmark, we first used Grad-CAM, Grad-CAM++, and Integrated Gradients to run 184 eighteen experiments, one for each combination of saliency method (Grad-CAM, Grad-185 CAM++, or Integrated Gradients) and CNN architecture (DenseNet121, ResNet152, or 186 Inception-v4) using one of the two evaluation metrics (mIoU or hit rate) (see Extended 187 Data Fig. 3). We also ran experiments to evaluate the localization performances of 188 DenseNet121 with Eigen-CAM, DeepLIFT, LRP, and Occlusion. We found that Grad-189 CAM with DenseNet121 generally demonstrated better localization performance across 190 pathologies and evaluation metrics than the other combinations of saliency method and 191 architecture (see Table 1 for localization performance on the test set of all seven saliency 192 methods using DenseNet121). Accordingly, we compared Grad-CAM with DenseNet121 193 ("saliency method pipeline") with the human benchmark using both mIoU and hit rate. The 194 localization performance for each pathology is reported on the true positive slice of the 195 dataset (CXRs that contain saliency method, human benchmark, and ground-truth 196 segmentations). Localization performance was calculated this way so that saliency 197 methods were not penalized by DNN classification error: while the benchmark radiologists

198 were provided with ground-truth labels when annotating the dataset, saliency method 199 segmentations were created based on labels predicted by the model. (See Extended Data 200 Fig. 4 for saliency method pipeline localization performance on the full dataset using

201 mloU.)

Ta	Table 1 Localization performance of saliency methods using DenseNet121							
Pa	athology	Grad-CAM	Grad-CAM++	Integrated Gradients	Eigen-CAM	DeepLIFT	LRP	Occlusion
mloU								
	Airspace Opacity	0.248	0.234	0.123	0.293	0.111	0.112	0.242
	Atelectasis	0.254	0.245	0.116	0.267	0.126	0.109	0.250
	Cardiomegaly	0.452	0.346	0.160	0.379	0.167	0.150	0.312
	Consolidation	0.408	0.297	0.177	0.332	0.088	0.099	0.212
	Edema	0.362	0.388	0.073	0.370	0.059	0.047	0.347
	Enlarged Cardiom.	0.379	0.400	0.154	0.372	0.109	0.117	0.363
	Lung Lesion	0.101	0.089	0.107	0.089	0.072	0.088	0.087
	Pleural Effusion	0.235	0.195	0.088	0.249	0.090	0.082	0.215
	Pneumothorax	0.213	0.218	0.077	0.218	0.084	0.066	0.214
	Support Devices	0.163	0.133	0.099	0.116	0.086	0.052	0.126
н	it rate							
	Airspace Opacity	0.498	0.558	0.606	0.566	0.528	0.566	0.367
	Atelectasis	0.501	0.621	0.520	0.530	0.415	0.468	0.343
	Cardiomegaly	0.903	0.732	0.697	0.709	0.610	0.644	0.515
	Consolidation	0.738	0.708	0.624	0.626	0.571	0.283	0.338
	Edema	0.746	0.781	0.300	0.758	0.468	0.156	0.469
	Enlarged Cardiom.	0.818	0.630	0.704	0.612	0.469	0.594	0.767
	Lung Lesion	0.290	0.290	0.423	0.146	0.497	0.356	0.072
	Pleural Effusion	0.507	0.347	0.332	0.439	0.408	0.283	0.291
	Pneumothorax	0.392	0.489	0.801	0.195	0.801	0.697	0.297
	Support Devices	0.355	0.364	0.491	0.216	0.598	0.264	0.189

202

We found that the saliency method pipeline demonstrated significantly worse localization performance when compared with the human benchmark using both mIoU (Fig. 2a) and hit rate (Fig. 2b) as an evaluation metric, regardless of model classification AUROC. For each metric, we report the 95% confidence intervals using the bootstrap method with 1,000 bootstrap samples⁴⁰. For five of the 10 pathologies, the saliency method pipeline

208 had a significantly lower mIoU than the human benchmark. For example, the saliency 209 method pipeline had one of the highest AUROC scores of the 10 pathologies for Support 210 Devices (0.969), but had among the worst localization performance for Support Devices 211 when using both mIoU (0.163 [95% CI 0.154, 0.172]) and hit rate (0.357 [95% CI 0.303, 212 0.408]) as evaluation metrics. On two pathologies (Atelectasis and Consolidation) the 213 saliency method pipeline significantly outperformed the human benchmark. On average, 214 across all 10 pathologies, mIoU saliency method pipeline performance was 26.6% [95% 215 CI 18.1%, 35.0%] worse than the human benchmark, with Lung Lesion displaying the 216 largest gap in performance (76.2% [95% CI 59.1%, 87.5%] worse than the human 217 benchmark) (Extended Data Fig. 5). Consolidation was the pathology on which the mIoU 218 saliency method pipeline performance exceeded the human benchmark the most, by 219 56.1% [95% CI 42.7%, 69.4%]. For seven of the 10 pathologies, the saliency method 220 pipeline had a significantly lower hit rate than the human benchmark. On average, hit rate 221 saliency method pipeline performance was 29.4% [95% CI 15.0%, 43.2%] worse than the 222 human benchmark (Extended Data Fig. 6), with Lung Lesion again displaying the largest 223 gap in performance (65.9% [95% CI 35.3%, 91.7%] worse than the human benchmark). 224 The hit rate saliency method pipeline did not significantly outperform the human 225 benchmark on any of the 10 pathologies; for the remaining three of the 10 pathologies, 226 the hit rate performance differences between the saliency method pipeline and the human 227 benchmark were not statistically significant. Therefore, while the saliency method pipeline 228 significantly underperformed the human benchmark regardless of evaluation metric used, 229 the average performance gap was larger when using hit rate as an evaluation metric than 230 when using mIoU as an evaluation metric.

231

We compared saliency method pipeline localization performance using an ensemble model to localization performance using the top performing single checkpoint for each pathology. We found that the single model has worse localization performance than the ensemble model for all pathologies when using mIoU and for six of the 10 pathologies when using hit rate (see Extended Data Fig. 7).





238 Fig. 2 | Evaluating localization performance. a, Comparing saliency method pipeline 239 and human benchmark localization performances under the overlap evaluation scheme 240 (mIoU). b, Comparing saliency method pipeline and human benchmark localization 241 performances under the hit rate evaluation scheme. For both **a** and **b**, pathologies, along 242 with their DenseNet121 AUROCs, are sorted on the x-axis first by statistical significance 243 of percentage decrease from human benchmark mIoU/hit rate to saliency method 244 pipeline mIoU/hit rate (high to low), and then by percentage decrease from human 245 benchmark mIoU/hit rate to saliency method pipeline mIoU/hit rate (high to low).

246

247 Characterizing underperformance of saliency method pipeline

248 In order to better understand the underperformance of the saliency method pipeline 249 localization, we first conducted a qualitative analysis with a radiologist by visually 250 inspecting both the segmentations produced by the saliency method pipeline (Grad-CAM 251 with DenseNet121) and the human benchmark segmentations. We found that, in general, 252 saliency method segmentations fail to capture the geometric nuances of a given 253 pathology, and instead produce coarse, low-resolution heat maps. Specifically, our 254 gualitative analysis found that the performance of the saliency method depended on three 255 pathological characteristics (Fig. 3a): (1) number of instances: when a pathology had 256 multiple instances on a CXR, the saliency method segmentation often highlighted one 257 large confluent area, instead of highlighting each distinct instance of the pathology 258 separately; (2) size: saliency method segmentations tended to be significantly larger than 259 human expert segmentations, often failing to respect clear anatomical boundaries; (3) 260 shape complexity: the saliency method segmentations for pathologies with complex 261 shapes frequently included significant portions of the CXR where the pathology is not 262 present.

Informed by our qualitative analysis and previous work in histology⁴⁵, we defined four 264 265 geometric features for our quantitative analysis (Fig. 3b): (1) number of instances (for 266 example, bilateral Pleural Effusion would have two instances, whereas there is only one 267 instance for Cardiomegaly), (2) size (pathology area with respect to the area of the whole 268 CXR), (3) elongation and (4) irrectangularity (the last two features measure the complexity 269 of the pathology shape and were calculated by fitting a rectangle of minimum area 270 enclosing the binary mask). See Extended Data Fig. 8 for the distribution of the four 271 pathological characteristics across all 10 pathologies.

272

273 For each evaluation metric, we ran 8 simple linear regressions: four with the evaluation 274 metric (IoU or hit rate) of the saliency method pipeline (Grad-CAM with DenseNet121) as 275 the dependent variable (to understand the relationship between the geometric features of 276 a pathology and saliency method localization performance), and four with the difference 277 between the evaluation metrics of the saliency method pipeline and the human 278 benchmark as the dependent variable (to understand the relationship between the 279 geometric features of a pathology and the gap in localization performance between the 280 saliency method pipeline and the human benchmark). Each regression used one of the 281 four geometric features as a single independent variable, and only the true positive slice 282 was included in each regression. Each feature was normalized using z-score 283 normalization and the regression coefficient can be interpreted as the effect of that 284 geometric feature on the evaluation metric at hand. See Table 2 for coefficients from the 285 regressions using both evaluation metrics, where we also report the 95% confidence

- interval and the Bonferroni corrected p-values. For confidence intervals and p-values, we
- used the standard calculation for linear models.





Airspace Opacity

Saliency method segmentation Ground-truth segmentation



Shape complexity Pleural Effusion

b

Edema

а



Number of instances = 1 Cardiomegaly



Elongation = low (1.44) Airspace Opacity

288



Number of instances = 2 Atelectasis



Elongation = high (5.43) Support Devices



Size = large (0.26) Enlarged Cardiomediastinum



Irrectangularity = low (0.24) Enlarged Cardiomediastinum



Size = small (0.006) Lung Lesion



Irrectangularlity = high (0.78) Pleural Effusion

289 Fig. 3 | Characterizing underperformance of saliency method pipeline. a. Example 290 CXRs that highlight the three pathological characteristics identified by our qualitative 291 analysis: (1) Left, number of instances; (2) Middle, size; and (3) Right, shape complexity. 292 **b**, Example CXRs with the four geometric features used in our guantitative analysis: (1) 293 Top row left, number of instances; (2) Top row right, size = area of segmentation/area of 294 CXR; (3) Bottom row left, elongation; and (4) Bottom row right, irrectangularity. 295 Elongation and irrectangularity were calculated by fitting a rectangle of minimum area 296 enclosing the binary mask (as indicated by the yellow rectangles). Elongation =

297 maxAxis/minAxis. Irrectangularity = 1 - (area of segmentation/area of enclosing 298 rectangle).

299

300 Our statistical analysis showed that as the area ratio of a pathology increased, mIoU 301 saliency method localization performance improved (0.566 [95% CI 0.526, 0.606]). We 302 also found that as elongation and irrectangularity increased, mIoU saliency method 303 localization performance worsened (elongation: -0.425 [95% CI -0.497, -0.354], 304 irrectangularity: -0.256 [95% CI -0.292, -0.219]). We observed that the effects of these 305 three geometric features were similar for hit rate saliency method localization 306 performance in terms of levels of statistical significance and direction of the effects. 307 However, there was no evidence that the number of instances of a pathology had a 308 significant effect on either mIoU (-0.115 [95% CI -0.220, -0.009]) or hit rate (-0.051 [95% 309 CI -0.364, 0.244]) saliency method localization. Therefore, regardless of evaluation 310 metric, saliency method localization performance suffered in the presence of pathologies 311 that were small in size and complex in shape.

312

We found that these same three pathological characteristics—larger size, and higher elongation and irrectangularity—characterized the *gap* in mIoU localization performance between saliency method and human benchmark. We observed that the *gap* in hit rate localization performance was significantly characterized by all four geometric features (number of instances, size, elongation, and irrectangularity). As the number of instances increased, despite no significant change in hit rate localization performance itself, the *gap* in hit rate localization performance between saliency method and the human benchmark

- increased (0.470 [95% CI 0.114, 0.825]). This suggests that the saliency method performs
- 321 especially poorly in the face of a multi-instance diagnosis.

Geometric feature (independent variable)		Coefficient using saliency method localization (dependent variable)	Coefficient using localization difference (human benchmark - saliency method) (dependent variable)			
lo	U					
	Number of instances	-0.115 (-0.220, -0.009)	-0.072 (-0.237, -0.094)			
	Size	0.566 (0.526, 0.606) ***	-0.154 (-0.231, -0.076) ***			
	Elongation	-0.425 (-0.497, -0.354) ***	0.476 (0.362, 0.589) ***			
	Irrectangularity	-0.256 (-0.292 -0.219) ***	0.307 (0.249, 0.366) ***			
н	it/Miss					
	Number of instances	-0.244 (-0.346, -0.051)	0.470 (0.114, 0.825) *			
	Size	1.269 (1.146, 1.391) ***	-0.944 (-1.104, -0.785) ***			
	Elongation	-0.849 (-1.053, -0.646) ***	1.110 (0.865, 1.354) ***			
	Irrectangularity	-0.519 (-0.624, -0.415) ***	0.689 (0.564, 0.815) ***			

Table 2 | Coefficients from regressions on geometric features of pathologies

322

323 Effect of model confidence on localization performance

* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001

324 We also conducted statistical analyses to determine whether there was any correlation between the model's confidence in its prediction and saliency method pipeline 325 performance (Table 3). We first ran a simple regression for each pathology using the 326 327 model's probability output as the single independent variable and using the saliency 328 method IoU as the dependent variable. We then performed a simple regression that uses 329 the same approach as above, but that includes all 10 pathologies. For each of the 11 330 regressions, we used the full dataset since the analysis of false positives and false 331 negatives was also of interest. In addition to the linear regression coefficients, we also

332 computed the Spearman correlation coefficients to capture any potential non-linear333 associations.

334

335 We found that for all pathologies, model confidence was positively correlated with mIoU 336 saliency method pipeline performance. The p-values for all coefficients were below 0.001 337 except for the coefficients for Pneumothorax (n=11) and Lung Lesion (n=50), the two pathologies for which we had the fewest positive examples. Of all the pathologies, model 338 339 confidence for positive predictions of Enlarged Cardiomediastinum had the largest linear 340 regression coefficient with mIoU saliency method pipeline performance (1.974, p-341 value<0.001). Model confidence for positive predictions of Pneumothorax had the largest 342 Spearman correlation coefficient with mIoU saliency method pipeline performance (0.734, 343 p-value<0.01), followed by Pleural Effusion (0.690, p-value<0.001). Combining all 344 pathologies (n=2365), the linear regression coefficient was 0.109 (95% CI [0.083, 0.135]), 345 and the Spearman correlation coefficient was 0.285 (95% CI [0.239, 0.331]). We also 346 performed analogous experiments using hit rate as the dependent variable and found 347 comparable results (Extended Data Fig. 9).

Table 3 mIoU: Coefficients from regressions on model assurance						
Pathology	CXRs (n)	Linear regression coefficient	Spearman correlation coefficient			
Airspace Opacity	381	0.714 (0.601, 0.826) ***	0.577 (0.542, 0.610) ***			
Atelectasis	296	0.489 (0.333, 0.645) ***	0.348 (0.303, 0.391) ***			
Cardiomegaly	229	0.679 (0.535, 0.823) ***	0.592 (0.559, 0.624) ***			
Consolidation	120	1.155 (0.674, 1.635) ***	0.384 (0.341, 0.426) ***			
Edema	124	0.642 (0.459, 0.826)***	0.548 (0.512, 0.582) ***			
Enlarged Cardiomediastinum	668	1.974 (1.608, 2.340) ***	0.428 (0.386, 0.468) ***			
Lung Lesion	50	0.218 (0.087, 0.349) **	0.509 (0.470, 0.545) ***			
Pleural Effusion	159	0.632 (0.489, 0.776) ***	0.690 (0.663, 0.715) ***			
Pneumothorax	11	0.446 (0.108, 0.783) *	0.734 (0.710, 0.756) **			
Support Devices	327	0.211 (0.172, 0.250) ***	0.468 (0.428, 0.506) ***			
All pathologies	2365	0.109 (0.083, 0.135) ***	0.285 (0.239, 0.331) ***			
* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001						

348

349 Discussion

350 The purpose of this work was to evaluate the performance of some of the most used 351 saliency methods for deep learning explainability using a variety of model architectures. 352 We establish the first human benchmark for CXR segmentation in a multilabel 353 classification setup and demonstrate that saliency maps are consistently worse than 354 expert radiologists regardless of model classification AUROC. We use gualitative and 355 quantitative analyses to establish that saliency method localization performance is most 356 inferior to expert localization performance when a pathology has multiple instances, is 357 smaller in size, or has shapes that are more complex, suggesting that deep learning 358 explainability as a clinical interface may be less reliable and less useful when used for 359 pathologies with those characteristics. We also show that model assurance is positively 360 correlated with saliency method localization performance, which could indicate that

361 saliency methods are safer to use as a decision aid to clinicians when the model has362 made a positive prediction with high confidence.

363

364 Because ground-truth segmentations for medical imaging are time-consuming and 365 expensive to obtain, the current norm in medical imaging-both in research and in 366 industry—is to use classification models on which saliency methods are applied post-hoc 367 for localization, highlighting the need for investigations into the reliability of these methods 368 in clinical settings^{46,47}. There are public CXR datasets containing image-level labels 369 annotated by expert radiologists (e.g., the CheXpert validation set), multilabel bounding box annotations (e.g., ChestX-ray8⁴⁸ and VinDr-CXR⁴⁹), and segmentations for a single 370 371 pathology (e.g., SIIM-ACR Pneumothorax Segmentation⁵⁰). To our knowledge, however, 372 there are no other publicly available CXR datasets with multilabel pixel-level expert 373 segmentations. By publicly releasing a development dataset, CheXlocalize, of 234 374 images with 885 expert segmentations, and a competition with a test set of 668 images, 375 we hope to encourage the further development of saliency methods and other 376 explainability techniques for medical imaging.

377

Our work has several potential implications for human-AI collaboration in the context of medical decision-making. Heat maps generated using saliency methods are advocated as clinical decision support in the hope that they not only improve clinical decisionmaking, but also encourage clinicians to trust model predictions⁵¹⁻⁵³. Many of the large CXR vendors^{54–56} use localization methods to provide pathology visualization in their computer-aided detection (CAD) products. In addition to being used for clinical

medRxiv preprint doi: https://doi.org/10.1101/2021.02.28.21252634; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

384 interpretation, saliency method heat maps are also used for the evaluation of CXR 385 interpretation models, for quality improvement (QI) and quality assurance (QA) in clinical 386 practices, and for dataset annotation⁵⁷. Explainable AI is critical in high-stakes contexts 387 such as health care, and saliency methods have been used successfully to develop and 388 understand models generally. Indeed, we found that the saliency method pipeline 389 significantly outperformed the human benchmark on two pathologies when using mIoU 390 as an evaluation metric. However, our work also suggests that saliency methods are not 391 yet reliable enough to validate individual clinical decisions made by a model. We found 392 that saliency method localization performance, on balance, performed worse than expert 393 localization across multiple analyses and across many important pathologies (our findings 394 are consistent with recent work focused on localizing a single pathology, Pneumothorax, 395 in CXRs⁵⁸). We hypothesize that this could be an algorithmic artifact of saliency methods, 396 whose relatively small heat maps (14x14 for Grad-CAM) are interpolated to the original 397 image dimensions (usually 2000x2000), resulting in coarse resolutions. If used in clinical 398 practice, heat maps that incorrectly highlight medical images may exacerbate well 399 documented biases (chiefly, automation bias) and erode trust in model predictions (even when model output is correct), limiting clinical translation²². 400

401

Since IoU computes the overlap of two segmentations but pointing game hit rate better captures diagnostic attention, we suggest using both metrics when evaluating localization performance in the context of medical imaging. While IoU is a commonly used metric for evaluating semantic segmentation outputs, there are inherent limitations to the metric in the pathological context. This is indicated by our finding that even the human benchmark

medRxiv preprint doi: https://doi.org/10.1101/2021.02.28.21252634; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

407 segmentations had low overlap with the ground truth segmentations (the highest expert 408 mIoU was 0.720 for Cardiomegaly). One potential explanation for this consistent underperformance is that pathologies can be hard to distinguish, especially without 409 410 clinical context. Furthermore, whereas many people might agree on how to segment, say, 411 a cat or a stop sign in traditional computer vision tasks, radiologists use a certain amount 412 of clinical discretion when defining the boundaries of a pathology on a CXR. There can 413 also be institutional and geographic differences in how radiologists are taught to 414 recognize pathologies, and studies have shown that there can be high interobserver 415 variability in the interpretation of CXRs^{59–61}. We sought to address this with the hit rate 416 evaluation metric, which highlights when two radiologists share the same diagnostic 417 intention, even if it is less exact than IoU in comparing segmentations directly. The human 418 benchmark localization using hit rate was above 0.9 for four pathologies (Pneumothorax, 419 Cardiomegaly, Support Devices, and Enlarged Cardiomediastinum); these are 420 pathologies for which there is often little disagreement between radiologists about where 421 the pathologies are located, even if the expert segmentations are noisy. Further work is 422 needed to demonstrate which segmentation evaluation metrics, even beyond overlap and 423 hit rate, are more appropriate for certain pathologies and downstream tasks when 424 evaluating saliency methods for the clinical setting.

425

Our work builds upon several studies investigating the validity of saliency maps for localization^{62,63,64} and upon some early work on the trustworthiness of saliency methods to explain DNNs in medical imaging⁴⁷. However, as recent work has shown³², evaluating saliency methods is inherently difficult given that they are post-hoc techniques. To

430 illustrate this, consider the following models and saliency methods as described by some 431 oracle: (1) a model *M* bad that has perfect AUROC for a given image classification task. 432 but that we know does not localize well (i.e. because the model picks up on confounders 433 in the image); (2) a model *M* good that also has perfect AUROC, but that we know does 434 localize well (i.e. is looking at relevant regions of the image); (3) a saliency method S bad 435 that does not properly reflect the model's attention; and (4) a saliency method S good 436 that does properly reflect the model's attention. Let us say that we are evaluating the 437 following pipeline: we first classify an image and we then apply a saliency method post 438 hoc. Imagine that our evaluation reveals poor localization performance as measured by 439 mIoU or hit rate (as was the case in our findings). There are three possible pipelines 440 (combinations of model and saliency method) that would lead to this scenario: (1) M bad 441 + S good; (2) M good + S bad; and (3) M bad + S bad. The first scenario (M bad + 442 S good) is the one for which saliency methods were originally intended: we have a 443 working saliency method that properly alerts us to models picking up on confounders. The 444 second scenario (*M* good + S bad) is our nightmare scenario: we have a working model 445 whose attention is appropriately directed, but we reject it based on a poorly localizing 446 saliency method. Because all three scenarios result in poor localization performance, it is 447 difficult—if not impossible—to know whether poor localization performance is attributable 448 to the model or to the saliency method (or to both). While we cannot say whether models 449 or saliency methods are failing in the context of medical imaging, we can say that we 450 should not rely on saliency methods to evaluate model localization. Future work should 451 explore potential techniques for localization performance attribution.

452

453 There are several limitations of our work. First, we did not investigate the impact of 454 pathology prevalence in the training data on saliency method localization performance. 455 Second, some pathologies, such as effusions and cardiomegaly, are in similar locations 456 across frontal view CXRs, while others, such as lesions and opacities, can vary in 457 locations across CXRs. Future work could investigate how the location of pathologies on 458 a CXR in the training/test data distribution, and the consistency of those locations, affect 459 saliency method localization performance. Third, while we compared saliency method-460 generated pixel-level segmentations to human expert pixel-level segmentations, future 461 work might explore how saliency method localization performance changes when 462 comparing bounding-box annotations, instead of pixel-level segmentations. Fourth, we 463 explored post-hoc interpretability methods given their prevalence in the context of medical 464 imaging, but we hope that by publicly releasing our development dataset of pixel-level 465 expert segmentations we can facilitate the development of models that make use of 466 ground-truth segmentations during training⁵⁷. Fifth, the lack of a given finding can in 467 certain cases inform clinical diagnoses. A common example of this is the lack of normal 468 lung tissue pattern towards the edges of the thoracic cage, which is used to detect 469 pneumothorax. For any characteristic pattern, both the absence and the presence provide 470 diagnostic information to the radiologist. For example, the absence of a pleural effusion 471 pattern is also used to rule out pleural effusion. For any characteristic radiological pattern, 472 both the presence as well as the absence contributes to the final radiology report. Future 473 work can explore counterfactual visual explanations that are similar to the counterfactual 474 diagnostic process of a radiologist. Sixth, future work should further explore the potentially 475 confounding effect of model calibration on the evaluation of saliency methods, especially

when using segmentation, as opposed to classification, models. Finally, the impact ofsaliency methods on the trust and efficacy of users is underexplored.

478

In conclusion, we present a rigorous evaluation of a range of saliency methods and a human benchmark dataset, which can serve as a foundation for future work exploring deep learning explainability techniques. This work is a reminder that care should be taken when leveraging common saliency methods to validate individual clinical decisions in deep learning-based workflows for medical imaging.

484

485 Methods

486 Ethical and information governance approvals.

487 A formal Stanford IRB review was conducted for the original collection of the CheXpert
488 dataset. The IRB waived the requirement to obtain informed consent as the data were
489 retrospectively collected and fully anonymized.

490

491 Dataset and clinical taxonomy. Dataset description. The localization experiments were 492 performed using CheXpert, a large public dataset for chest X-ray interpretation. The 493 CheXpert dataset contains 224,316 chest X-rays for 65,240 patients labeled for the 494 presence of 14 observations (13 pathologies and an observation of "No Finding") as 495 positive, negative, or uncertain. The CheXpert validation set consists of 234 chest X-rays 496 from 200 patients randomly sampled from the full dataset and was labeled according to 497 the consensus of three board-certified radiologists. The test set consists of 668 chest X-498 rays from 500 patients not included in the training or validation sets and was labeled

499 according to the consensus of five board-certified radiologists. See Extended Data Fig.500 10 for test set summary statistics.

501

502 Ground-truth segmentation. The chest X-rays in our validation set and test set were 503 manually segmented by two board-certified radiologists with 18 and 27 years of 504 experience, using the annotation software tool MD.ai⁶⁵ (see Supplementary Figs. S12 505 through S14). The radiologists were asked to contour the region of interest for all 506 observations in the chest X-rays for which there was a positive ground truth label in the 507 CheXpert dataset. For a pathology with multiple instances, all the instances were 508 contoured. For Support Devices, radiologists were asked to contour any implanted or 509 invasive devices including pacemakers, PICC/central catheters, chest tubes, 510 endotracheal tubes, feeding tubes and stents and ignore ECG lead wires or external 511 stickers visible in the chest X-ray.

512

513 Evaluating the expert performance using benchmark segmentation. To evaluate the 514 expert performance on the test set using the IoU evaluation method, three radiologists, 515 certified in Vietnam with 9, 10, and 18 years of experience, were asked to segment the 516 regions of interest for all observations in the chest X-rays for which there was a positive 517 ground truth label in the CheXpert dataset. These radiologists were also provided the 518 same instructions for contouring as were provided to the radiologists drawing the 519 reference segmentations. To extract the "maximally activated" point from the benchmark 520 segmentations, we asked the same radiologists to locate each pathology present on each 521 CXR using only a single most representative point for that pathology on the CXR (see

522 Supplementary Figs. S1 through S11 for the detailed instructions given to the 523 radiologists). There was no overlap between these three radiologists and the two who 524 drew the reference segmentations.

525

526 Classification network architecture and training protocol. Multi-label classification 527 model. The model takes as input a single-view chest X-ray and outputs the probability for 528 each of the 14 observations. In case of availability of more than one view, the models 529 output the maximum probability of the observations across the views. Each chest X-ray 530 was resized to 320×320 pixels and normalized before it was fed into the network. We used the same image resolutions as CheXpert³⁶ and CheXnet², which demonstrated 531 532 radiologist-level performance on external test sets with 320x320 images. There are 533 models that are commercially deployed and have similar dimensions. For example, the 534 architecture used by a medical AI software vendor Annalise.ai⁶⁶ is based on 535 EfficientNet⁶⁷, which takes input of 224x224. Chest X-rays were normalized prior to being 536 fed into the network by subtracting the mean of all images in the CheXpert training set 537 and then dividing by the standard deviation of all images in the CheXpert training set. The 538 model architectures (DenseNet121, ResNet152, and Inception-v4) were used. Cross-539 entropy loss was used to train the model. The Adam optimizer⁶⁸ was used with default β -540 parameters of $\beta 1 = 0.9$ and $\beta 2 = 0.999$. The learning rate was hyperparameter tuned for 541 the different model architectures. Grid search was used to tune the learning rates. We 542 searched over learning rates of 1e-3, 1e-4, and 1e-5. The best learning rate for each 543 architecture was: 1×10-4 for DenseNet121, 1×10-5 for ResNet152, 1×10-5 for 544 Inceptionv4. Batches were sampled using a fixed batch size of 16 images.

545

546 Ensembling. We use an ensemble of checkpoints to create both predictions and saliency 547 maps to maximize model performance. In order to capture uncertainties inherent in 548 radiograph interpretation, we train our models using four uncertainty handling strategies 549 outlined in CheXpert: Ignoring, Zeroes, Ones, and 3-Class Classification. For each of the 550 four uncertainty handling strategies, we train our model three separate times, each time 551 saving the 10 checkpoints across the three epochs with the highest average AUC across 552 5 observations selected for their clinical importance and prevalence in the validation set: 553 Atelectasis, Cardiomegaly, Consolidation, Edema, and Pleural Effusion. In total, after 554 training, we have saved $4 \times 30 = 120$ checkpoints for a given model. Then, from the 120 555 saved checkpoints for that model, we select the top 10 performing checkpoints for each 556 pathology. For each CXR and each task, we compute the predictions and saliency maps 557 using the relevant checkpoints. We then take the mean both of the predictions and of the 558 saliency maps to create the final set of predictions and saliency maps for the ensemble 559 model. See Supplementary Table S1 for the performance of each model architecture 560 (DenseNet121, ResNet152, and Inception-v4) on each of the pathologies.

561

562 **CNN interpretation strategy.** Saliency methods were used to visualize the decision 563 made by the classification network. The saliency map was resized to the original image 564 dimension using bilinear interpolation. It was then normalized using max-min 565 normalization and then converted into a binary segmentation using binary thresholding 566 (Otsu's method). We also reported mIoU localization performance using different saliency 567 map thresholding values. We first applied max-min normalizations to the saliency maps

568 so that each value gets transformed into a decimal between 0 and 1. We then passed in 569 a range of threshold values from 0.2 to 0.8 to create binary segmentations and calculated 570 the mIoU score per pathology under each threshold on the validation set. Then for the 571 analysis on the full dataset (see Extended Data Fig. 4), we further ensure that the final 572 binary segmentation is consistent with model probability output by applying another layer 573 of thresholding such that the segmentation mask produced all zeros if the predicted 574 probability was below a chosen level. The probability threshold is searched on the interval 575 of [0,0.8] with steps of 0.1. The exact value is determined per pathology by maximizing 576 the mIoU on validation set.

577

578 For Occlusion, we used a window size of 40 and a stride of 40 for each CXR.

579

580 Segmentation evaluation metrics. Localization performance of each segmentation was 581 evaluated using Intersection over Union (IoU) score. The IoU is the ratio between the 582 area of overlap and the area of union between the ground truth and the predicted areas, 583 ranging from 0 to 1 with 0 signifying no overlap and 1 signifying perfectly overlapping 584 segmentation. Confidence intervals are calculated using bootstrapping with 1000 585 bootstrap samples. The variance in the width of CI across pathologies can be explained 586 by difference in sample sizes. For the percentage decrease from expert mIoU to AI mIoU, 587 we bootstrapped the difference between human benchmark and saliency method 588 localization and created the 95% confidence intervals. The confidence intervals for hit 589 rates were calculated in the same fashion. For the evaluation of Integrated Gradients 590 using IoU, we applied box filtering of kernel size 100 to smooth the pixelated map. For

591 DeepLIFT, we applied box filtering of kernel size 50. For LRP, we used a kernel size of 592 80. The kernel sizes are tuned on the validation set. The noisy map is not a concern for 593 hit rate because a single max pixel is extracted for the entire image.

594

595 Statistical analysis.

596 Pathology Characteristics. We used four features to characterize the pathologies. (1) 597 Number of instances is defined as the number of disjoint components in the 598 segmentation. (2) Size is the area of the pathology divided by the total image area. (3) 599 and (4) Elongation and irrectangularity are geometric features that measure shape 600 complexities. They were designed to quantify what radiologists qualitatively described as 601 focal or diffused. To calculate the metrics, a rectangle of minimum area enclosing the 602 contour is fitted to each pathology. Elongation is defined as the ratio of the rectangle's 603 longer side to short side. Irrectangularity = 1 - (area of segmentation/area of enclosing 604 rectangle), with values ranging from 0 to 1 with 1 being very irrectangular. When there 605 are multiple instances within one pathology, we used the characteristics of the dominant 606 instance (largest in perimeter).

607

608 *Model Confidence.* We used the probability output of the DNN architecture for model 609 confidence. The probabilities were normalized using max-min normalization per 610 pathology before aggregation.

611

Linear Regression. For each evaluation scheme (overlap and hit rate), we ran two groups
 of simple linear regressions, with AI evaluation metrics and their differences as the

- 614 response variables. Each group has four regressions using the above four pathological 615 characteristics as the regressions' single attribute, respectively, and only the true positive 616 slice was included in each regression. All features are normalized using min-max 617 normalization so that they are comparable on scales of magnitudes. We report the 95%
- 618 confidence interval and Bonferroni adjusted p-value of the regression coefficients.
- 619

620 Data Availability

- 621 The CheXlocalize dataset is available here:
- 622 https://stanfordaimi.azurewebsites.net/datasets/abfb76e5-70d5-4315-badc-
- 623 <u>c94dd82e3d6d</u>. The CheXpert dataset is available here
- 624 https://stanfordmlgroup.github.io/competitions/chexpert/.
- 625

626 **Code Availability**

- 627 The code used to generate segmentations from saliency method heat maps, fine-tune
- 628 segmentation thresholds, generate segmentations from human annotations, and evaluate
- 629 localization performance is available in the following public repository under the MIT
- 630 License: <u>https://github.com/rajpurkarlab/cheXlocalize</u>. The version used for this
- 631 publication is available at <u>https://doi.org/10.5281/zenodo.6816288</u>69.
- 632

633 Acknowledgements

We would like to acknowledge MD.ai for generously providing us access to their annotation platform. We would like to acknowledge Weights & Biases for generously providing us access to their experiment tracking tools.

637

638 Author Contributions

- 639 Conceptualization: P.R. and A.P. Design: P.R., A.P., A.S., X.G. and A.A. Data analysis
- and interpretation: A.S., X.G., A.A., P.R., A.P., S.T., C.N., V.N., J.S., and F.B. Drafting of
- the manuscript: A.S., X.G., A.A., and P.R. Critical revision of the manuscript for important
- 642 intellectual content: A.P, S.T., C.N., V.N., J.S., F.B, A.N., and M.L. Supervision: A.N.,
- 643 M.L., and P.R. Research was primarily performed while A.S. was at Stanford University.
- 644 M.L. and P.R. contributed equally.

645

646 **Competing Interests**

- 647 M.L. is an advisor for and/or has research funded by GE, Philips, Carestream, Nines
- Radiology, Segmed, Centaur Labs, Microsoft, BunkerHill, and Amazon Web Services
- 649 (none of the funded research was relevant to this project). A.P. is a medical associate at
- 650 Cerebriu. The remaining authors declare no competing interests.

651

652 **References**

- 1. Rajpurkar, P. et al. Deep learning for chest radiograph diagnosis: A retrospective
- 654 comparison of the CheXNeXt algorithm to practicing radiologists. *PLOS Med.* **15**,
- 655 e1002686 (2018).
- 656 2. Rajpurkar, P. et al. CheXNet: Radiologist-Level Pneumonia Detection on Chest X-
- 657 Rays with Deep Learning. *ArXiv171105225 Cs Stat* (2017).

- 3. Bien, N. et al. Deep-learning-assisted diagnosis for knee magnetic resonance
- 659 imaging: Development and retrospective validation of MRNet. *PLOS Med.* **15**,
- 660 e1002699 (2018).
- 4. Baselli, G., Codari, M. & Sardanelli, F. Opening the black box of machine learning in
- radiology: can the proximity of annotated cases be a way? *Eur. Radiol. Exp.* **4**, 30
- 663 (2020).
- 5. Litjens, G. *et al.* A survey on deep learning in medical image analysis. *Med. Image Anal.* 42, 60–88 (2017).
- 666 6. Wang, F., Kaushal, R. & Khullar, D. Should Health Care Demand Interpretable
- Artificial Intelligence or Accept "Black Box" Medicine? *Ann. Intern. Med.* **172**, 59–60
 (2019).
- 669 7. Goodman, B. & Flaxman, S. European Union regulations on algorithmic decision-
- 670 making and a 'right to explanation'. *AI Mag.* **38**, 50–57 (2017).
- 8. Venugopal, V. K., Takhar, R., Gupta, S., Saboo, A. & Mahajan, V. Clinical
- 672 Explainability Failure (CEF) & Explainability Failure Ratio (EFR) changing the way
- 673 we validate classification algorithms? J Med Syst **46**, 20 (2022).
- 9. Pasa, F., Golkov, V., Pfeiffer, F., Cremers, D. & Pfeiffer, D. Efficient Deep Network
- Architectures for Fast Chest X-Ray Tuberculosis Screening and Visualization. *Sci. Rep.* 9, 6268 (2019).
- 10. Simonyan, K., Vedaldi, A. & Zisserman, A. Deep Inside Convolutional Networks:
- 678 Visualising Image Classification Models and Saliency Maps. *ArXiv13126034 Cs*
- 679 (2014).

- Aggarwal, M. *et al.* Towards Trainable Saliency Maps in Medical Imaging.
 ArXiv201107482 Cs Eess (2020).
- 12. Tjoa, E. & Guan, C. Quantifying Explainability of Saliency Methods in Deep
- 683 Neural Networks. *ArXiv200902899 Cs* (2020).
- 13. Badgeley, M. A. *et al.* Deep learning predicts hip fracture using confounding
- patient and healthcare variables. *Npj Digit. Med.* **2**, 31 (2019).
- 14. Zech, J. R. *et al.* Variable generalization performance of a deep learning model
- to detect pneumonia in chest radiographs: A cross-sectional study. *PLOS Med.* **15**,
- 688 e1002683 (2018).
- 15. DeGrave, A. J., Janizek, J. D. & Lee, S.-I. AI for radiographic COVID-19
- detection selects shortcuts over signal. Nat Mach Intell **3**, 610-619 (2021).
- 691 16. Makimoto, H. et al. Performance of a convolutional neural network derived from
- an ECG database in recognizing myocardial infarction. *Sci. Rep.* **10**, 8445 (2020).
- 693 17. Porumb, M., Stranges, S., Pescapè, A. & Pecchia, L. Precision Medicine and
- 694 Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events
- 695 Detection based on ECG. *Sci. Rep.* **10**, 1–16 (2020).
- 696 18. Tham, Y.-C. et al. Referral for disease-related visual impairment using retinal
- 697 photograph-based deep learning: a proof-of-concept, model development study.
- 698 *Lancet Digit. Health* **3**, e29–e40 (2021).
- 699 19. Varadarajan, A. V. *et al.* Deep Learning for Predicting Refractive Error From
- Retinal Fundus Images. Invest. Ophthalmol. Vis. Sci. 59, 2861–2868 (2018).
- 701 20. Mitani, A. et al. Detection of anaemia from retinal fundus images via deep
- 702 learning. *Nat. Biomed. Eng.* **4**, 18–27 (2020).

703	21.	Deep Learning to Assess Long-term Mortality From Chest Radiographs
704	Pu	Ilmonary Medicine JAMA Network Open JAMA Network. https://jamanetwork-
705	<u>C0</u>	m.stanford.idm.oclc.org/journals/jamanetworkopen/fullarticle/2738349.
706	22.	Rajpurkar, P. et al. CheXaid: deep learning assistance for physician diagnosis of
707	tuk	perculosis using chest x-rays in patients with HIV. Npj Digit. Med. 3, 1–8 (2020).
708	23.	Rajpurkar, P. et al. AppendiXNet: Deep Learning for Diagnosis of Appendicitis
709	fro	m A Small Dataset of CT Exams Using Video Pretraining. Sci. Rep. 10, 3958
710	(20	020).
711	24.	Huang, SC. et al. PENet—a scalable deep-learning model for automated
712	dia	agnosis of pulmonary embolism using volumetric CT imaging. Npj Digit. Med. 3, 1–
713	9 (2020).
714	25.	Rudin, C. Stop explaining black box machine learning models for high stakes
715	de	cisions and use interpretable models instead. Nat. Mach. Intell. 1, 206–215 (2019).
716	26.	Eitel, F. & Ritter, K. Testing the Robustness of Attribution Methods for
717	Co	prvolutional Neural Networks in MRI-Based Alzheimer's Disease Classification.
718	Int	erpretability of Machine Intelligence in Medical Image Computing and Multimodal
719	Le	arning for Clinical Decision Support (eds. Suzuki, K. et al.) 3-11 (Springer
720	Int	ernational Publishing, 2019). doi:10.1007/978-3-030-33850-3_1.
721	27.	Young, K., Booth, G., Simpson, B., Dutton, R. & Shrapnel, S. Deep Neural
722	Ne	etwork or Dermatologist? in Interpretability of Machine Intelligence in Medical Image
723	Сс	omputing and Multimodal Learning for Clinical Decision Support (eds. Suzuki, K. et
724	al.) 48–55 (Springer International Publishing, 2019). doi:10.1007/978-3-030-33850-
725	3_	6.

726	28.	Ghassemi, M., Oakden-Rayner, L. & Beam, A. L. The false hope of current
727	ар	proaches to explainable artificial intelligence in health care. Lancet Digit. Health 3,
728	e7	45–e750 (2021).
729	29.	Reyes, M. et al. On the Interpretability of Artificial Intelligence in Radiology:
730	Ch	allenges and Opportunities. Radiol. Artif. Intell. 2 , e190043 (2020).
731	30.	Selvaraju, R. R. et al. Grad-CAM: Visual Explanations from Deep Networks via
732	Gr	adient-based Localization. Int. J. Comput. Vis. 128, 336–359 (2020).
733	31.	Chattopadhay, A., Sarkar, A., Howlader, P. & Balasubramanian, V. N. Grad-
734	CA	M++: Generalized Gradient-Based Visual Explanations for Deep Convolutional
735	Ne	etworks. in 2018 IEEE Winter Conference on Applications of Computer Vision
736	(W	/ACV) 839–847 (2018). doi:10.1109/WACV.2018.00097.
737	32.	Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. in
738	Pr	oceedings of the 34th International Conference on Machine Learning - Volume 70
739	33	19–3328 (JMLR.org, 2017).
740	33.	Huang, G., Liu, Z., Van Der Maaten, L. & Weinberger, K. Q. Densely Connected
741	Co	prvolutional Networks. in 2017 IEEE Conference on Computer Vision and Pattern
742	Re	cognition (CVPR) 2261–2269 (IEEE, 2017). doi:10.1109/CVPR.2017.243.
743	34.	He, K., Zhang, X., Ren, S. & Sun, J. Deep Residual Learning for Image
744	Re	cognition. in 2016 IEEE Conference on Computer Vision and Pattern Recognition
745	(C	<i>VPR</i>) 770–778 (IEEE, 2016). doi:10.1109/CVPR.2016.90.
746	35.	Szegedy, C. et al. Going deeper with convolutions. in 2015 IEEE Conference on
747	Сс	omputer Vision and Pattern Recognition (CVPR) 1–9 (2015).
748	do	i:10.1109/CVPR.2015.7298594.

- 749 36. Irvin, J. *et al.* CheXpert: A Large Chest Radiograph Dataset with Uncertainty
- Labels and Expert Comparison. *Proc. AAAI Conf. Artif. Intell.* **33**, 590–597 (2019).
- 751 37. Otsu, N. A Threshold Selection Method from Gray-Level Histograms. *IEEE Trans*
- 752 Syst. Man Cybern. 62–66 (1979).
- 753 38. Zhang, J. et al. Top-down Neural Attention by Excitation Backprop. Int. J.
- 754 Comput. Vis. **126**, 1084-1102 (2018).
- 755 39. Kim, H.-E. et al. Changes in cancer detection and false-positive recall in
- 756 mammography using artificial intelligence: a retrospective, multireader study. *Lancet*
- 757 *Digit. Health* **2**, e138–e148 (2020).
- 40. Efron, B. & Tibshirani, R. J. An Introduction to the Bootstrap. (CRC Press, 1994).
- 759 41. Bany Muhammad, M. et al. Eigen-CAM: Visual Explanations for Deep
- 760 Convolutional Neural Networks. SN COMPUT. SCI. 2, 47 (2021).
- 761 42. Shrikumar, A., Greenside, P. & Kundaje, A. Learning Important Features
- 762 Through Propagating Activation Differences. In International conference on machine
- 763 *learning* 3145-3153 (PMLR, 2017).
- 43. Bach, S. et al. On Pixel-Wise Explanations for Non-Linear Classifier Decisions by
- Layer-Wise Relevance Propagation. PLOS ONE 10, e0130140 (2015).
- 766 44. Zeiler, M. D. & Fergus, R. Visualizing and Understanding Convolutional
- 767 Networks. in *Computer Vision ECCV 2014* (eds. Fleet, D., Pajdla, T., Schiele, B. &
- Tuytelaars, T.) 818–833 (Springer International Publishing, 2014). doi:10.1007/978-3-
- 769 319-10590-1_53.
- 45. Vrabac, D. *et al.* DLBCL-Morph: Morphological features computed using deep
- learning for an annotated digital DLBCL image set. *Sci Data* **8**, 135 (2021).

- 46. Ayhan, M. S. et al. Clinical validation of saliency maps for understanding deep
- neural networks in ophthalmology. Med. Image Anal. 77, 102364 (2022).
- 47. Arun, N. et al. Assessing the Trustworthiness of Saliency Maps for Localizing
- Abnormalities in Medical Imaging. Radiol. Artif. Intell. 3, e200267 (2021).
- 48. Wang, X. et al. ChestX-ray8: Hospital-Scale Chest X-Ray Database and
- 777 Benchmarks on Weakly-Supervised Classification and Localization of Common
- 778 Thorax Diseases. in 2017 IEEE Conference on Computer Vision and Pattern
- 779 *Recognition (CVPR)* 2097–2106 (IEEE, 2017).
- 49. Nguyen, H. Q. et al. VinDr-CXR: An open dataset of chest X-rays with radiologist's
- 781 annotations. (2022) doi:10.48550/arXiv.2012.15029.
- 782 50. SIIM-ACR Pneumothorax Segmentation. https://kaggle.com/c/siim-acr-
- 783 <u>pneumothorax-segmentation</u>.
- 51. Steiner, D. F. et al. Impact of Deep Learning Assistance on the Histopathologic
- Review of Lymph Nodes for Metastatic Breast Cancer. Am. J. Surg. Pathol. 42,
- 786 **1636–1646 (2018)**.
- 52. Uyumazturk, B. et al. Deep Learning for the Digital Pathologic Diagnosis of
- 788 Cholangiocarcinoma and Hepatocellular Carcinoma: Evaluating the Impact of a Web-
- based Diagnostic Assistant. *ArXiv191107372 Eess* (2019).
- 790 53. Park, A. et al. Deep Learning–Assisted Diagnosis of Cerebral Aneurysms Using
- the HeadXNet Model. JAMA Netw. Open 2, e195600 (2019).
- 792 54. Annalise.ai Medical imaging AI, by clinicians for clinicians. Annalise.ai
- 793 <u>https://annalise.ai/</u>.
- 794 55. Lunit Inc. <u>https://www.lunit.io/en</u>.

795	56.	Qure.ai	Artificial	Intelligence	for Radiology.	https://gure.ai/.

- 57. Gadgil, S., Endo, M., Wen, E., Ng, A. Y. & Rajpurkar, P. CheXseg: Combining
- 797 Expert Annotations with DNN-generated Saliency Maps for X-ray Segmentation. In
- 798 Proceedings of the Fourth Conference on Medical Imaging with Deep Learning 190-
- 799 **204 (PMLR, 2021)**.
- 58. Crosby, J., Chen, S., Li, F., MacMahon, H. & Giger, M. Network output
- 801 visualization to uncover limitations of deep learning detection of pneumothorax. in
- 802 Medical Imaging 2020: Image Perception, Observer Performance, and Technology
- Assessment vol. 11316 1131600 (International Society for Optics and Photonics,
- 804 2020).
- 805 59. Melbye, H. & Dale, K. Interobserver Variability in the Radiographic Diagnosis of
 806 Adult Outpatient Pneumonia. *Acta Radiol.* 33, 79–81 (1992).
- 807 60. Herman, P. G. *et al.* Disagreements in Chest Roentgen Interpretation. *CHEST*808 68, 278–282 (1975).
- 809 61. Albaum, M. N. et al. Interobserver Reliability of the Chest Radiograph in
- 810 Community-Acquired Pneumonia. *CHEST* **110**, 343–350 (1996).
- 811 62. Arun, N. T. et al. Assessing the validity of saliency maps for abnormality
- localization in medical imaging. In *Medical Imaging with Deep Learning.* (2020).
- 813 63. Graziani, M., Lompech, T., Müller, H. & Andrearczyk, V. Evaluation and
- 814 Comparison of CNN Visual Explanations for Histopathology. (2020).
- 815 64. Choe, J. et al. Evaluating Weakly Supervised Object Localization Methods Right.
- 816 In Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern
- 817 *Recognition* 3133-3142 (IEEE, 2020).

- 818 65. MD.ai. https://www.md.ai/.
- 819 66. Seah, J. C. Y. et al. Effect of a comprehensive deep-learning model on the
- 820 accuracy of chest x-ray interpretation by radiologists: a retrospective, multireader
- multicase study. Lancet Digit. Health 3, e496–e506 (2021).
- 822 67. Tan, M. & Le, Q. V. EfficientNet: Rethinking Model Scaling for Convolutional
- 823 Neural Networks. In International conference on machine learning 6105-6114 (PMLR,
- 824 2020).
- 825 68 Kingma, D. P. & Ba, J. Adam: A Method for Stochastic Optimization.
- 826 ArXiv14126980 Cs (2017).
- 827 69. Saporta, A. et al. Code for 'Benchmarking saliency methods for chest X-ray
- 828 interpretation' (Zenodo, 2022); https://doi.org/10.5281/zenodo.6816288.

830 Extended Data





832

Extended Data Fig. 1 | mIoU localization performance of the saliency method 833 834 pipeline using threshold values tuned on the validation set. a, We first applied max-835 min normalizations to the Grad-CAM saliency maps so that each value gets transformed 836 into a decimal between 0 and 1. We then passed in a range of threshold values from 0.2 837 to 0.8 to create binary segmentations and plotted the mIoU score per pathology under 838 each threshold on the validation set. The threshold that gives the max mIoU for each pathology is marked with an "X". Pathologies are sorted alphabetically and shown in two 839 840 plots for readability. b, Comparing mIoU localization performances of the saliency method pipeline (using the best thresholds tuned on the validation set) and the human 841 benchmark. We found that the saliency method pipeline outperformed the human 842 843 benchmark on two pathologies and underperformed the human benchmark on five pathologies. For the remaining three pathologies, the performance differences were not 844 845 statistically significant. This finding is consistent with what we report in the manuscript using Otsu's method. 846

	specificity (precision)		sensitivity (recall)	
pathology	saliency method pipeline	human benchmark	saliency method pipeline	human benchmark
Airspace Opacity	0.844	0.982	0.975	0.961
Atelectasis	0.854	0.999	0.985	0.971
Cardiomegaly	0.914	0.998	0.978	0.986
Consolidation	0.916	1.000	0.998	0.995
Edema	0.851	0.997	0.988	0.980
Enlarged Cardiom.	0.935	0.993	0.938	0.958
Lung Lesion	0.887	1.000	1.000	1.000
Pleural Effusion	0.808	0.999	0.994	0.987
Pneumothorax	0.866	1.000	1.000	1.000
Support Devices	0.862	0.997	0.980	0.979

848 849

849 Extended Data Fig. 2 | Specificity and sensitivity values of the saliency method

pipeline and human benchmark. For each pathology, we highlight the higher of the two metrics (saliency method pipeline or human benchmark) in **bold**.

		Grad-CAM			Grad-CAM++		In	tegrated Gradie	nts
pathology	DenseNet121	ResNet152	Inception-v4	DenseNet121	ResNet152	Inception-v4	DenseNet121	ResNet152	Inception-v4
mloU									
Airspace Opacity	0.248	0.194	0.090	0.234	0.198	0.115	0.123	0.119	0.052
Atelectasis	0.254	0.221	0.115	0.245	0.210	0.106	0.116	0.115	0.064
Cardiomegaly	0.452	0.424	0.120	0.346	0.257	0.196	0.160	0.154	0.089
Consolidation	0.408	0.334	0.079	0.296	0.245	0.130	0.177	0.112	0.069
Edema	0.362	0.240	0.203	0.388	0.345	0.266	0.073	0.062	0.099
Enlarged Cardiom.	0.379	0.272	0.065	0.400	0.382	0.295	0.154	0.152	0.094
Lung Lesion	0.101	0.066	0.003	0.089	0.069	0.045	0.107	0.063	0.001
Pleural Effusion	0.235	0.204	0.120	0.195	0.176	0.090	0.088	0.091	0.067
Pneumothorax	0.213	0.171	0.088	0.216	0.184	0.124	0.077	0.070	0.078
Support Devices	0.163	0.147	0.116	0.133	0.126	0.099	0.099	0.074	0.066
hit rate									
Airspace Opacity	0.498	0.428	0.106	0.558	0.522	0.148	0.606	0.586	0.122
Atelectasis	0.501	0.490	0.062	0.621	0.621	0.118	0.520	0.453	0.187
Cardiomegaly	0.903	0.915	0.126	0.732	0.297	0.493	0.697	0.748	0.268
Consolidation	0.738	0.797	0.030	0.708	0.600	0.284	0.624	0.538	0.115
Edema	0.746	0.432	0.385	0.781	0.745	0.457	0.300	0.350	0.180
Enlarged Cardiom.	0.818	0.627	0.030	0.630	0.631	0.731	0.704	0.730	0.205
Lung Lesion	0.290	0.146	0.000	0.290	0.146	0.000	0.423	0.211	0.000
Pleural Effusion	0.507	0.499	0.133	0.347	0.473	0.107	0.332	0.400	0.182
Pneumothorax	0.392	0.600	0.000	0.489	0.698	0.097	0.801	0.498	0.097
Support Devices	0.355	0.287	0.133	0.364	0.334	0.150	0.491	0.442	0.324

853 854

Extended Data Fig. 3 | Test set localization performance for each combination of

saliency method and CNN architecture. For each pathology and saliency method, we
 highlight the highest performing CNN architecture in **bold**.



858 859

859 Extended Data Fig. 4 | Saliency method pipeline localization performance on the

full dataset using mIoU. True negatives (CXRs whose ground-truth label is negative
 for a given pathology and for which there were neither human benchmark nor saliency

862 method pipeline segmentations for that pathology) were excluded from the metric

calculation. To control for false positives, we ensure that the final binary segmentation is

consistent with model probability output by applying another layer of thresholding such
 that the segmentation mask produced all zeros if the predicted probability was below a

866 chosen level. The probability threshold is searched on the interval of [0,0.8] with steps

of 0.1. The exact value is determined per pathology by maximizing the mIoU on the

validation set. We found that on the full dataset, for seven of the 10 pathologies, the

saliency method pipeline had a significantly lower mIoU than the human benchmark.

pathology	human benchmark mloU	saliency method pipeline mloU	% decrease (95% Cl)
Lung Lesion	0.426	0.101	76.2 (59.1, 87.5)
Support Devices	0.444	0.163	63.3 (60.8, 65.8)
Pneumothorax	0.435	0.213	51.0 (14.6, 69.5)
Cardiomegaly	0.720	0.452	37.2 (34.0, 40.4)
Enlarged Cardiom.	0.569	0.379	33.4 (29.0, 37.4)
Airspace Opacity	0.260	0.248	4.6 (-5.8, 14.6)
Pleural Effusion	0.219	0.235	-6.8 (-25.6, 13.3)
Edema	0.335	0.362	-7.4 (-16.4, 2.6)
Atelectasis	0.124	0.254	-51.2 (-57.3, -43.9)
Consolidation	0.179	0.408	-56.1 (-69.4, -42.7)
Average	0.383	0.281	26.6 (18.1, 35.0)

871 872 Extended Data Fig. 5 | Percentage decrease from human benchmark mIoU to 873 saliency method pipeline mIoU. Pathologies are sorted first by statistical significance 874 of percentage decrease from human benchmark mIoU to saliency method pipeline 875 mIoU (high to low), and then by percentage decrease from human benchmark mIoU to 876 saliency method pipeline mIoU (high to low). We use 95% bootstrap confidence interval. 877

pathology	human benchmark hit rate (%)	saliency method pipeline hit rate (%)	% decrease (95% Cl)
Lung Lesion	0.850	0.290	65.9 (35.3, 91.7)
Support Devices	0.933	0.355	62.0 (56.2, 67.5)
Pneumothorax	1.000	0.392	60.8 (27.3, 92.3)
Atelectasis	0.870	0.501	42.4 (0.3, 0.5)
Pleural Effusion	0.718	0.507	29.4 (14.3, 42.5)
Enlarged Cardiom.	0.957	0.818	14.5 (9.6, 19.2)
Cardiomegaly	0.972	0.903	7.1 (2.1, 11.8)
Airspace Opacity	0.559	0.498	10.9 (-2.0, 23.1)
Edema	0.769	0.746	3.0 (-11.7, 18.5)
Consolidation	0.510	0.738	-44.7 (-56.5, 0.5)
Average	0.820	0.580	29.4 (15.0, 43.2)

878 879 Extended Data Fig. 6 | Percentage decrease from human benchmark hit rate to

880 saliency method pipeline hit rate. Pathologies are sorted first by statistical

881 significance of percentage decrease from human benchmark hit rate to saliency method

pipeline hit rate (high to low), and then by percentage decrease from human benchmark 882

883 hit rate to saliency method pipeline hit rate (high to low). We use 95% bootstrap

884 confidence interval.

pathology	ensemble model	single checkpoint
mloU		
Airspace Opacity	0.248	0.241
Atelectasis	0.254	0.233
Cardiomegaly	0.452	0.419
Consolidation	0.408	0.369
Edema	0.362	0.360
Enlarged Cardiom.	<u>0.379</u>	0.297
Lung Lesion	0.101	0.099
Pleural Effusion	0.235	0.205
Pneumothorax	0.213	0.181
Support Devices	0.163	0.150
hit rate		
Airspace Opacity	0.498	0.534
Atelectasis	0.501	0.504
Cardiomegaly	0.903	0.846
Consolidation	0.738	0.711
Edema	0.746	0.749
Enlarged Cardiom.	<u>0.818</u>	0.704
Lung Lesion	0.290	0.286
Pleural Effusion	0.507	0.390
Pneumothorax	0.392	0.491
Support Devices	0.355	0.312

886 887 Extended Data Fig. 7 | Saliency method pipeline localization performance using

an ensemble model vs. using the top performing single checkpoint for each 888

pathology. For each pathology, we highlight in **bold** the model (ensemble or single 889

checkpoint) that has the higher metric, and we <u>underline</u> it if the difference is statistically 890

significant (using 95% bootstrap confidence interval). 891



893 894

894 Extended Data Fig. 8 | Distribution of four geometric features across all 10

pathologies. The black horizontal line in each box indicates the median feature value
 for that pathology, and each successive level outward contains half of the remaining
 data. The height of the box indicates the range of feature values in the quantile.

pathology	CXRs (<i>n</i>)	Linear regression coefficient	Spearman correlation coefficient
Airspace Opacity	381	0.498***	0.160**
Atelectasis	296	0.443**	0.126
Cardiomegaly	229	0.195*	0.185*
Consolidation	120	0.082	0.199
Edema	124	0.195	0.132
Enlarged Cardiom.	668	0.548**	0.253***
Lung Lesion	50	0.540	0.453
Pleural Effusion	159	0.654***	0.278**
Pneumothorax	11	0.210	0.142
Support Devices	327	-0.058	-0.029
All pathologies	2365	-0.411***	-0.239***

* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001

899

900 Extended Data Fig. 9 | Hit rate: Coefficients from regressions on model

901 assurance.

sample size	
Number studies	500
Number CXRs	668
pathology	CXRs (<i>n</i>)
Airspace Opacity	309
Atelectasis	177
Cardiomegaly	175
Consolidation	35
Edema	83
Enlarged Cardiom.	297
Lung Lesion	14
Pleural Effusion	120
Pneumothorax	10
Support Devices	314
No pathology identified	169

⁹⁰³ 904

⁶⁴ Extended Data Fig. 10 | Test set summary statistics.